Evidence map›Paper›PMID 32528214›Full record

ArticleProceedings of SPIE--the International Society for Optical Engineering2020

Enhancement of label-free biosensing of cardiac troponin I.

Chase Christenson, Kwaku Baryeh, Samad Ahadian, Rohollah Nasiri, Mehmet R Dokmeci, Marcus Goudie, Ali Khademhosseini, Jing Yong Ye

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of SPIE--the International Society for Optical Engineering, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Nano-porous anodic alumina: fundamentals and applications in tissue engineering.Journal of materials science. Materials in medicine · 2020
    Review
  8. Micro and nanoscale technologies in oral drug delivery.Advanced drug delivery reviews · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chase ChristensonDepartment of Biomedical Engineering, University of Texas at San Antonio, One UTSA Circle, San Antonio, TX 78249, USA.
Kwaku BaryehDepartment of Biomedical Engineering, University of Texas at San Antonio, One UTSA Circle, San Antonio, TX 78249, USA.
Samad AhadianDepartment of Chemical and Biomolecular Engineering, Department of Bioengineering, University of California Los Angeles, CA 90095, USA.
Rohollah NasiriDepartment of Chemical and Biomolecular Engineering, Department of Bioengineering, University of California Los Angeles, CA 90095, USA.
Mehmet R DokmeciDepartment of Chemical and Biomolecular Engineering, Department of Bioengineering, University of California Los Angeles, CA 90095, USA.
Marcus GoudieDepartment of Chemical and Biomolecular Engineering, Department of Bioengineering, University of California Los Angeles, CA 90095, USA.
Ali KhademhosseiniDepartment of Chemical and Biomolecular Engineering, Department of Bioengineering, University of California Los Angeles, CA 90095, USA.
Jing Yong YeDepartment of Biomedical Engineering, University of Texas at San Antonio, One UTSA Circle, San Antonio, TX 78249, USA.

Funding

Research Supplements to Promote DiversityR01GM126571 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DOKMECI, MEHMET REMZI, YE, JING YONG · 2018 to 2021
$1.3M
NIGMS NIH HHS R01 GM126571
6 · The paper itself

Abstract

The detection of cardiac troponin I (cTnI) is clinically used to monitor myocardial infarctions (MI) and other heart diseases. The development of highly sensitive detection assays for cTnI is needed for the efficient diagnosis and monitoring of cTnI levels. Traditionally, enzyme-based immunoassays have been used for the detection of cTnI. However, the use of label-free sensing techniques have the advantage of potentially higher speed and lower cost for the assays. We previously reported a Photonic Crystal-Total Internal Reflection (PC-TIR) biosensor for label-free quantification of cTnI. To further improve on this, we present a comparative study between an antibody based PC-TIR sensor that relies on recombinant protein G (RPG) for the proper orientation of anti-cTnI antibodies, and an aptamer-based PC-TIR sensor for improved sensitivity and performance. Both assays relied on the use of polyethylene glycol (PEG) linkers to facilitate the modification of the sensor surfaces with biorecognition elements and to provide fluidity of the sensing surface. The aptamer-based PC-TIR sensor was successfully able to detect 0.1 ng/mL of cTnI. For the antibody-based PC-TIR sensor, the combination of the fluidity of the PEG and the increased number of active antibodies allowed for an improvement in assay sensitivity with a low detection limit of 0.01 ng/mL. The developed assays showed good performance and potential to be applied for the detection of cTnI levels in clinical samples upon further development.

Indexed as

AptamerBiosensingCardiac Troponin ILabel-FreeMyocardial InfarctionPhotonic Crystal-Total Internal Reflection

Identifiers

PMID32528214
PMCPMC7288396

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.